PMID- 33230478
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201125
IS  - 2162-2531 (Print)
IS  - 2162-2531 (Electronic)
IS  - 2162-2531 (Linking)
VI  - 22
DP  - 2020 Dec 4
TI  - Circular RNA circRIMS1 Acts as a Sponge of miR-433-3p to Promote Bladder Cancer 
      Progression by Regulating CCAR1 Expression.
PG  - 815-831
LID - 10.1016/j.omtn.2020.10.003 [doi]
AB  - Circular RNAs (circRNAs), a subclass of noncoding RNAs, are reportedly involved 
      in the progression of various diseases. However, the exact role of circRIMS1, 
      also termed hsa_circ_0132246, in human bladder cancer remains unknown. By 
      performing RNA sequencing comparing bladder cell lines and normal uroepithelial 
      cells, circRIMS1 was selected as a research object. We further verified by 
      qRT-PCR that circRIMS1 is upregulated in both bladder cancer tissue and cell 
      lines. Proliferation, colony-formation, Transwell migration, invasion, apoptosis, 
      western blotting, and in vivo experiments were utilized to clarify the roles of 
      circRIMS1, microRNA (miR)-433-3p, and cell cycle and apoptosis regulator 1 
      (CCAR1). For mechanistic investigation, RNA pulldown, fluorescence in situ 
      hybridization (FISH), and luciferase reporter assay confirmed the binding of 
      circRIMS1 with miR-433-3p. Inhibition of circRIMS1 suppressed the proliferation, 
      migration, and invasion of bladder cancer cells both in vitro and in vivo. 
      Moreover, the circRIMS1/miR-433-3p/CCAR1 regulatory axis was confirmed to be 
      responsible for the biological functions of circRIMS1. Taken together, our 
      research demonstrated that circRIMS1 promotes tumor growth, migration, and 
      invasion through the miR-433-3p/CCAR1 regulatory axis, representing a potential 
      therapeutic target and biomarker in bladder cancer.
CI  - (c) 2020 The Author(s).
FAU - Wang, Feifan
AU  - Wang F
AD  - Department of Urology, The First Affiliated Hospital, Zhejiang University School 
      of Medicine, Hangzhou, Zhejiang 310003, PR China.
FAU - Fan, Mengjing
AU  - Fan M
AD  - Department of Pathology, Sir Run Shaw Hospital, Zhejiang University School of 
      Medicine, Hangzhou, Zhejiang 310016, PR China.
FAU - Cai, Yueshu
AU  - Cai Y
AD  - Department of Urology, The First Affiliated Hospital, Zhejiang University School 
      of Medicine, Hangzhou, Zhejiang 310003, PR China.
FAU - Zhou, Xuejian
AU  - Zhou X
AD  - Department of Urology, The First Affiliated Hospital, Zhejiang University School 
      of Medicine, Hangzhou, Zhejiang 310003, PR China.
FAU - Tai, Shengcheng
AU  - Tai S
AD  - Department of Urology, The First Affiliated Hospital, Zhejiang University School 
      of Medicine, Hangzhou, Zhejiang 310003, PR China.
AD  - Department of Urology, Xiaoshan Hospital, Hangzhou, Zhejiang 311200, PR China.
FAU - Yu, Yanlan
AU  - Yu Y
AD  - Department of Urology, Sir Run Shaw Hospital, Zhejiang University School of 
      Medicine, Hangzhou, Zhejiang 310016, PR China.
FAU - Wu, Hongshen
AU  - Wu H
AD  - Department of Urology, The First Affiliated Hospital, Zhejiang University School 
      of Medicine, Hangzhou, Zhejiang 310003, PR China.
FAU - Zhang, Yan
AU  - Zhang Y
AD  - Department of Urology, The First Affiliated Hospital, Zhejiang University School 
      of Medicine, Hangzhou, Zhejiang 310003, PR China.
FAU - Liu, Jiaxin
AU  - Liu J
AD  - Department of Urology, The First Affiliated Hospital, Zhejiang University School 
      of Medicine, Hangzhou, Zhejiang 310003, PR China.
FAU - Huang, Shihan
AU  - Huang S
AD  - Department of Urology, The First Affiliated Hospital, Zhejiang University School 
      of Medicine, Hangzhou, Zhejiang 310003, PR China.
FAU - He, Ning
AU  - He N
AD  - Department of Urology, The First Affiliated Hospital, Zhejiang University School 
      of Medicine, Hangzhou, Zhejiang 310003, PR China.
FAU - Hu, Zhenghui
AU  - Hu Z
AD  - Department of Urology, The First Affiliated Hospital, Zhejiang University School 
      of Medicine, Hangzhou, Zhejiang 310003, PR China.
FAU - Jin, Xiaodong
AU  - Jin X
AD  - Department of Urology, The First Affiliated Hospital, Zhejiang University School 
      of Medicine, Hangzhou, Zhejiang 310003, PR China.
LA  - eng
PT  - Journal Article
DEP - 20201010
PL  - United States
TA  - Mol Ther Nucleic Acids
JT  - Molecular therapy. Nucleic acids
JID - 101581621
PMC - PMC7658378
OTO - NOTNLM
OT  - CCAR1
OT  - bladder cancer
OT  - circRIMS1
OT  - miR-433-3p
OT  - progression
EDAT- 2020/11/25 06:00
MHDA- 2020/11/25 06:01
PMCR- 2020/10/10
CRDT- 2020/11/24 06:05
PHST- 2020/06/18 00:00 [received]
PHST- 2020/10/06 00:00 [accepted]
PHST- 2020/11/24 06:05 [entrez]
PHST- 2020/11/25 06:00 [pubmed]
PHST- 2020/11/25 06:01 [medline]
PHST- 2020/10/10 00:00 [pmc-release]
AID - S2162-2531(20)30315-2 [pii]
AID - 10.1016/j.omtn.2020.10.003 [doi]
PST - epublish
SO  - Mol Ther Nucleic Acids. 2020 Oct 10;22:815-831. doi: 10.1016/j.omtn.2020.10.003. 
      eCollection 2020 Dec 4.